Supportive care in hematologic malignancies.
Supportive care in hematologic malignancies includes a wide range of topics. We have selected the following issues for a review of recently published developments: new insights into the benefits and risks of established hematopoietic growth factors (HGF), such as granulocyte- or granulocyte-macrophage colony-stimulating factor (G-CSF, GM-CSF); the emerging role of newly introduced HGFs such as keratinocyte-growth factor (KGF) and thrombopoietin; the prophylactic and therapeutic use of amifostine, a cytoprotective agent; the role of hematopoietic growth factors and the demethylating agent decitabine in myelodysplastic syndromes (MDS); infectious complications of anticancer therapy; and, recent improvements in and complications of transfusional therapy, including the renewed interest in granulocyte transfusions.
Fetscher
S
S
Department of Internal Medicine, Freiburg University Medical Center, Freiburg im Breisgau, Germany.
Mertelsmann
R
R
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003141:Communicable Diseases / Q000209:etiology / Q000628:therapy; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy*; D016298:Hematopoietic Cell Growth Factors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D065227:Transfusion Reaction
D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors